Search Results (53)

Hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV), together with HIV and bacterial sexually transmitted infections (STIs), account for a rising toll of more than one million deaths annually and overlap within shared behavioral and social networks, yet are still diagnosed through separate, pathogen-specific pathways. This narrative review synthesizes contemporary evidence on the convergence between viral hepatitis, HIV, and high-risk STI groups—men who have sex with men, pre-exposure prophylaxis (PrEP) users, people practicing chemsex, people who inject drugs, incarcerated populations, and migrants from endemic regions—and characterizes the diagnostic technologies and linkage-to-care models available to address it. Despite effective antivirals, the diagnostic cascade remains the principal bottleneck: most people with chronic HCV are undiagnosed, and HDV—with a pooled anti-HDV seroprevalence of approximately 4.5% among HBsAg-positive individuals—is its clearest expression, as most carriers are never tested. Reflex algorithms, multiplex panels, point-of-care assays, dried blood spots, and electronic health record alerts are validated but unevenly implemented. We argue that, alongside persistent resource, political, and equity-related constraints, a substantial share of the remaining barriers is operational rather than purely technological, and propose a practical, STI-clinic-centered framework integrating reflex testing, population-specific periodicity, and explicit linkage pathways toward the WHO 2030 elimination targets. Full article

Mother-to-child transmission (MTCT) of infectious diseases remains a public health challenge in socially vulnerable regions with limited healthcare access. This study assessed the epidemiological situation, spatial distribution, and socioeconomic context of MTCT infections—Chagas disease (ChD), syphilis, HIV, and hepatitis B (HB)—in the Gran Chaco region (Argentina–Paraguay), 2018–2024. Epidemiological data from 2877 patients enrolled in an MTCT Plus programme were analysed, alongside socioeconomic variables and spatio-temporal cluster analysis using SaTScan software. Maternal seroprevalence of ChD was 4.1%, the highest among the infections evaluated. Syphilis prevalence was 0.8%, while no HIV or HBV infections were detected among screened pregnant women. Two statistically significant spatiotemporal clusters of maternal Trypanosoma cruzi seropositivity were identified: a household-level cluster in 2018 and a regional cluster during 2019–2021. The highest prevalence of maternal ChD seropositivity was observed in census tracts with greater socioeconomic vulnerability, although this spatial overlap was assessed descriptively. These findings highlight the effectiveness of integrated maternal–child health services in ensuring coverage, timely diagnosis, and treatment in vulnerable populations. The identified spatial patterns provide evidence to support targeted surveillance and coordinated binational public health strategies in border regions affected by persistent social inequalities. Full article

Hepatitis B virus (HBV) infection remains a major public-health challenge in Peru, particularly in historically hyperendemic Amazonian and Andean regions; however, the structure, evolution, and equity of national HBV research have not been systematically evaluated. We conducted a PRISMA-informed bibliometric analysis of all peer-reviewed and theses on HBV in Peru published between 1988 and 2023 using Scopus, Google Scholar, and the Peruvian National Repository (RENATI). Bibliometric indicators, collaboration networks, thematic structure, and temporal thematic evolution were analyzed in R using bibliometrix- and network-based approaches. The final corpus comprised 232 documents, with a marked increase in production after 2005 and a publication peak in 2018. Scientific output was strongly concentrated in Lima-based institutions, while several departments historically associated with HBV endemicity exhibited minimal or absent research production. Nearly half of the corpus corresponded to undergraduate and postgraduate theses. Thematic analyses revealed persistent predominance of epidemiology, seroprevalence, and vaccination-related research, whereas molecular virology, therapeutics, and translational research remained peripheral or poorly represented. International collaboration was markedly limited. Overall, Peruvian HBV research has expanded quantitatively but remains geographically centralized and shows only limited correspondence with the contemporary geographic distribution of HBV incidence, while also remaining only partially aligned with the contemporary global HBV research frontier. These findings provide an evidence-based framework to guide research-priority setting, territorial equity policies, and strategic investment in infectious disease research capacity in Peru. Moreover, the weak association observed between scientific production and departmental HBV incidence suggests that factors beyond contemporary epidemiological burden contribute to the current distribution of research activity in Peru, highlighting a critical but often overlooked dimension of health inequity in low- and middle-income countries (LMIC) research systems. Full article

The importation of hepatitis B virus (HBV) variants through migration challenges elimination efforts in low-endemicity countries. This study evaluated the seroprevalence, occult hepatitis B infection (OBI), and molecular signatures of HBV among 537 international migrants from 46 countries who arrived in St. Petersburg, Russia. HBsAg, anti-HBs, and anti-HBc were measured by ELISA. This was followed by nested real-time PCR targeting viral genes (S, X) and a human housekeeping gene (HPRT, internal control), amplification of overlapping fragments covering the complete HBV genome, and Sanger sequencing. HBsAg prevalence was 2.61% (95% CI: 1.43–4.34), while anti-HBc was detected in 16.39% (95% CI: 13.36–19.79). HBV DNA was found in 8.19% (44/537; 95% CI: 6.02–10.04) of migrants. Notably, OBI (HBsAg-negative/HBV DNA-positive) was identified in 33 individuals, yielding a prevalence of 6.15% (33/537; 95% CI: 4.27–8.52) in the entire cohort and 6.31% among HBsAg-negative subjects. The findings among OBI cases were as follows: the majority (54.5%) had no detectable anti-HBc or anti-HBs; 30.3% were positive for anti-HBs only; 6.06% were positive for anti-HBc IgG only; 9.09% of cases featured both anti-HBc and anti-HBs. Viral loads in OBI cases were uniformly low (14–53 IU/mL). Genotype D predominated (86.36%, 38/44). The distribution of subgenotypes among all sequenced isolates was as follows: D1 in 36.36% (16/44), D2 in 36.36% (16/44), D3 in 13.64% (6/44), while genotypes A2 (6.82%, 3/44), B4 (4.55%, 2/44), and C2 (2.27%, 1/44) were rare. In the major hydrophilic region (MHR), the most frequent amino acid substitutions were at positions T127P/I (61.4%) and T118R/M/V/A (45.5%). Immune escape mutations were significantly associated with OBI (81.82% of OBI cases versus 18.18% of HBsAg-positive cases; p = 0.003). Drug resistance mutations (L180M + M204V ± T184A) were detected in 11.4% of isolates (all genotype D2). In the precore region, stop codon mutation W28* was found in 31.82% of samples, and the A1762T/G1764A double substitution in the basal core promoter occurred in 25.0%. The high prevalence of OBI, coupled with the accumulation of escape and drug resistance mutations in imported HBV variants, highlights the urgent need to include molecular HBV screening in mandatory medical examinations for arriving migrants to prevent undetected transmission and inform clinical management in receiving countries. Full article

The hepatitis B (HBV), C (HCV), and D (HDV) viruses remain a major public health burden. Occult HBV infection (OBI) represents a hidden reservoir with clinical and epidemiological significance, yet its prevalence in Northwest Russia is unknown. We aimed to comprehensively assess the serological and molecular epidemiology of HBV, HCV, and HDV in St. Petersburg and the Leningrad region. Methods. In this cross-sectional study, 6773 apparently healthy volunteers were enrolled. Plasma samples were tested for hepatitis B surface antigen (HBsAg), antibodies to HBV core antigen (anti-HBc), antibodies to HBsAg (anti-HBs), antibodies to HCV (anti-HCV), and antibodies to HDV (anti-HDV) by ELISA. All anti-HCV- and anti-HDV-positive samples were tested for HCV RNA and HDV RNA by real-time PCR. All samples were tested for HBV DNA using a highly sensitive in-house nested real-time PCR assay (detection limit: 5 IU/mL). All “HBV DNA-positive, HBsAg-negative” cases confirmed by two independent extractions were classified as OBI. Vaccination status, self-reported history, and iatrogenic interventions were recorded. Results. Overall seroprevalence values were: HBsAg 1.7%; anti-HBc 11.3%; anti-HBs 43.0%; anti-HCV 1.9%; and anti-HDV 0.6%. Anti-HBc increased sharply with age (3.1% in children to 26.4% in the elderly, p < 0.0001), while anti-HBs declined (69.9% to 29.8%, p < 0.0001). HBV DNA was detected in 118 participants (1.7%). Of these, only 73 individuals (1.1%) were HBsAg-positive, while the remaining 45 participants (0.7%) had undetectable HBsAg, meeting the criteria for OBI. OBI was detected across all age groups, including children. Serological profiling of OBI cases revealed that 57.8% lacked both anti-HBc and anti-HBs, 35.6% had isolated anti-HBs, 2.2% had isolated anti-HBc, and 4.4% had both antibodies. HCV RNA was detected in 15.0% of anti-HCV-positive individuals (all adults). No HDV RNA was detected. Self-reported history underestimated true infection rates: 1.4% of those denying HBV infection were HBsAg-positive and 10.6% were anti-HBc-positive. Among those denying HCV infection, 1.4% were anti-HCV-positive. Vaccination coverage was 70.8%, declining from 90.9% in children to 39.0% in the elderly (p < 0.0001). Among vaccinated individuals, 48.0% lacked protective anti-HBs (<10.0 mIU/mL). Conclusions. This comprehensive serological and molecular study in Northwest Russia is the first to combine population-level serology with molecular detection of HBV, HCV, and HDV, including OBI in this region, and reveals that OBI accounts for a substantial proportion (38%) of all active HBV infections and is strongly associated with a history of iatrogenic interventions. The presence of OBI across all age groups, including children, shows that HBsAg screening alone substantially underestimates the true HBV burden. High rates of unrecognized infection and waning vaccine-induced immunity, highlight critical gaps in current surveillance. These findings provide an evidence-based rationale for integrating molecular testing into screening algorithms and for considering booster vaccination strategies to achieve viral hepatitis elimination goals. Full article

Background/Objectives: Hepatitis B remains a major public health concern in the Democratic Republic of the Congo (DRC). This study investigated HBV seroprevalence in Kinshasa and evaluated the diagnostic performance of rapid diagnostic tests (RDTs) compared with dried blood spot (DBS)–based immunoassays. Methods: DBS samples collected between 2016 and 2022 were transported to Spain for HBsAg and HBc-Ab testing using two chemiluminescence platforms (ECLIA-COBAS (Roche) and ELFA-miniVIDAS (bioMerieux)). A subset of participants also underwent on-site HBsAg screening using Determine™ (Abbott) RDTs. Results: Overall, active HBV infection was detected in 4.3% of participants and resolved infection in 14.3%, with no significant differences by age, sex, cohort, or HIV/HCV status. The RDT showed poor sensitivity (60% (95% CI: 26–88)) but high specificity (100% (95% CI: 98–100)), resulting in a 40% misdiagnosis rate. In contrast, DBS-based HBsAg immunoassays demonstrated excellent diagnostic accuracy, with both platforms achieving 100% sensitivity (ECLIA-COBAS 100%, 95% CI: 66–100; ELFA-miniVIDAS 100%, 95% CI: 99–100) and specificity (ECLIA-COBAS 100%, 95% CI: 98–100; ELFA-miniVIDAS 100%, 95% CI: 99–100). HBc-Ab detection showed platform-dependent variability, with lower sensitivity on ELFA-miniVIDAS (66% (95% CI: 46–82)) compared with ECLIA-COBAS (100% (95% CI: 96–100)). Predictive values were high across all assays, and inter-method agreement for HBsAg between RDT and chemiluminescence was good (Cohen’s kappa 0.71, p < 0.001). Conclusions: These findings indicate moderate HBV transmission in Kinshasa and highlight the limited reliability of RDT-based screening. DBS proved to be a practical, robust, and scalable sampling method with outstanding diagnostic performance, making it well-suited for HBV testing in low-resource settings. Full article

Background/Objectives: Tunisia lacks recent national data on hepatitis B virus (HBV) prevalence, particularly following the introduction of universal HBV vaccination in 1995. A national HBV seroprevalence study is essential to guide prevention strategies. This study aimed to estimate the national seroprevalence of HBV infection and identify its determinants 20 years after vaccine introduction. Methods: We conducted a nationwide, household-based, cross-sectional sero-epidemiological survey among a representative sample of the Tunisian general population using a two-stage cluster sampling method. The study was conducted by the National Observatory of New and Emerging Diseases (ONMNE) between December 2014 and June 2015. Data were collected using standardized questionnaires, and blood samples were tested using electrochemiluminescence (ECLIA) to detect HBV biomarkers (HBsAg, anti-HBc, anti-HBs). HBV infection was defined as the presence of HBsAg and/or anti-HBc with the absence of anti-HBs. Associations between HBV infection and explanatory variables (socio-demographics, vaccination status, intrafamilial transmission, and hospital exposures) were assessed using multivariate logistic regression, reporting adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Results: Among 21,720 participants, 19,155 (88.2%) were tested. The national prevalence of HBsAg was 1.7% (95% CI: 1.55–1.85%), higher among males (2.1%; 95% CI: 1.9–2.4%) than females (1.4%; 95% CI: 1.3–1.6%) (p < 0.001; M/F ratio = 1.48). The mean age of HBsAg-positive participants was 48 ± 15.7 years. Prevalence was highest in the Central (2.3%; 95% CI: 2.0–2.7%) and Southern regions (2.2%; 95% CI: 1.8–2.8%) (p < 0.001). In multivariate analysis, independent risk factors for HBV infection included age >20 years (aOR = 15.10; 95% CI: 4.79–47.64; p < 0.001), having a family member with HBV infection (aOR = 2.82; 95% CI: 2.09–3.79; p < 0.001), residing in the Southern (aOR = 2.51; 95% CI: 1.76–2.71; p < 0.001) or Central region (aOR = 2.18; 95% CI: 1.76–2.71; p < 0.001), male gender (aOR = 1.69; 95% CI: 1.39–2.05; p < 0.001), and hospital follow-up (aOR = 1.23; 95% CI: 1.01–1.51; p = 0.039). HBV vaccination was strongly protective (aOR = 0.36; 95% CI: 0.20–0.62; p < 0.001). Conclusions: The national HBsAg seroprevalence in Tunisia was 1.7%, reflecting a low-endemic status. Vaccination programs should prioritize high-risk groups, including males, adults over 20 years, household contacts of HBV carriers, and residents of the Central and Southern regions. Strengthening infection prevention and control in healthcare settings and adopting intrafamilial precautions among high-risk populations are essential for long-term HBV control. Full article

Background: Hemodialysis patients are particularly vulnerable to hepatitis B virus (HBV) due to immunosuppression and repeated vascular access. While universal childhood vaccination has reduced population-level HBV prevalence, dialysis units require tailored prevention and monitoring strategies. This study aimed to characterize HBV serologic profiles, evaluate immune responses, and assess the kinetics of antibody waning in a diverse hemodialysis population. Methods: We retrospectively analyzed 565 adult hemodialysis patients (2015–2024), assessing HBV seroprevalence, seroconversion, booster response, and antibody waning. Subgroup comparisons were made by ethnicity and birth cohort (pre- vs. post-1992 national vaccine rollout). Time-to-waning analyses were performed using Kaplan–Meier methods. Results: HBsAg and anti-HBc were positive in 4.1% and 31.7% of patients, respectively; 3.7% were HCV seropositive. No HBsAg seroconversions occurred, and 2.1% of initially anti-HBc-negative patients seroconverted. Among patients with isolated anti-HBc, 80.9% developed protective anti-HBs titers, and none became HBsAg- or HBV DNA-positive. Waning anti-HBs titers occurred in 67.5% (median: 7.3 months), with 87.4% demonstrating a serologic response following documented vaccine delivery. Patients born after 1992 showed higher isolated anti-HBs positivity and lower anti-HBc prevalence. Ethnic subgroup analysis showed higher exposure rates but similar booster response among minority patients. Conclusions: HBV serologic profiles in this hemodialysis cohort reflected the interplay of immunosuppression, vaccination practices, and evolving epidemiologic trends. Subgroups exhibited variable vaccine responses, differing patterns of antibody waning, and a low incidence of new infections. These findings support tailored, population-specific HBV monitoring and prevention strategies in dialysis care. Full article

Chronic hepatitis B virus (HBV) and Occult HBV infection (OBI) remain a health burden in sub-Saharan Africa. This study investigated HBV prevalence, circulating genotypes, and associated risk factors with HBV exposure among HIV-positive adults on antiretroviral therapy and pregnant women in southwestern Cameroon. A total of 233 HIV patients and 190 third-trimester pregnant women were screened for HBV DNA, viral load, serological markers (HBsAg, anti-HBc, and anti-HBs), and HBV genotypes were determined by partial sequencing of the S gene. HBV DNA was detected in 10% of HIV-positive patients and 4% of pregnant women, with an overall prevalence of 7%. OBI accounted for 9% and 3%, respectively. Anti-HBc seroprevalence was high (75% in HIV, 46% in pregnant women), while self-reported vaccination coverage was low (1% and 11%). Genotypes A, B, D, and E were identified, with genotype B reported for the first time in Cameroon. Immune escape mutations and the adefovir resistance mutation rtA181V were detected. Self-reported alcohol use was associated with HBV exposure in HIV patients (aOR = 2.08; p = 0.028) and inversely associated with tertiary education in pregnant women (aOR = 0.18; p = 0.038). This study highlights a significant burden of HBV and OBI among vulnerable populations in Cameroon. Full article

Background: Since the introduction of the hepatitis B virus (HBV) vaccination program in Oman in 1990, the HBV prevalence has markedly decreased. However, hepatitis D virus (HDV) infection, which is associated with progressive liver disease in patients with chronic HBV, remains understudied in the Omani population. This study aimed to estimate HDV’s seroprevalence, characterize its virological and clinical features, and identify factors associated with anti-HDV positivity among adult Omani patients with chronic HBV infection. Methods: We conducted a multicenter cross-sectional study in 2024 at two referral hospitals and two polyclinics in Oman. Adult Omani patients with chronic HBV (HBsAg-positive for >6 months) were enrolled. Demographic, clinical, laboratory, imaging, and elastography data were collected. The total anti-HDV antibodies were tested using an ELISA; HDV RNA was tested for anti-HDV-positive or equivocal results. Liver Fibrosis was assessed non-invasively through liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE); FibroScan^® and clinical evaluation. Ridge (penalized) logistic regression identified predictors independently associated with anti-HDV positivity. Results: Among 639 patients (59.3% male; mean age of 46.6 ± 8.8 years), 36 patients were anti-HDV-positive, resulting in an HDV seroprevalence of 5.6% (95% CI: Exact 3.98–7.71; Wilson 4.10–7.70). Only one anti-HDV-positive patient had detectable HDV RNA, which became undetectable on follow-up without HDV treatment. The anti-HDV-positive patients were more frequently female and had a higher frequency of prior blood transfusions. In a penalized multivariable analysis, blood transfusions were independently associated with anti-HDV positivity (OR of 19.94), whereas male sex was associated with lower odds of being anti-HDV-positive (OR of 0.15). All the anti-HDV-positive patients had mild fibrosis (F0–F1). Conclusions: Our study demonstrated an anti-HDV prevalence of 5.63% among adult Omani patients with chronic HBV infection, while active viremia appeared to be rare. Blood transfusions were the main identified risk factor. Given the very low HDV viremia, targeted screening of higher-risk groups may be efficient. Full article

Background/Objectives: Hepatitis B virus (HBV) remains a persistent challenge for transfusion safety. Although testing for hepatitis B surface antigen (HBsAg) and nucleic acid testing (NAT) reduces transmission risk, antibodies to hepatitis B core antigen (anti-HBc) and antibodies to hepatitis B surface antigen (anti-HBs) provide additional insight into past infection and vaccine-induced immunity. We aimed to determine their seroprevalence among blood donors in southern Croatia and assess associations with age, occupation, and time since vaccination. Methods: This cross-sectional study was conducted between February and November 2024 at two regional transfusion centers in southern Croatia. A total of 1008 voluntary blood donors, all HBsAg- and NAT-negative, were tested for anti-HBc and anti-HBs using chemiluminescent microparticle immunoassay. Demographic and vaccination data were collected through verified medical records. Results: Anti-HBc was detected in 0.5% of donors, exclusively among the unvaccinated. Protective anti-HBs levels were found in 38.1% overall and 70.6% of vaccinated donors, with significant declines by age and more than 15 years post-vaccination (p = 0.024). Healthcare workers showed higher seroprotection than non-healthcare donors (67.0% vs. 35.1%; p < 0.001), although one-third still lacked protective levels. Conclusions: HBV exposure was rare, but waning vaccine-induced immunity was evident, with protective anti-HBs levels in 70.6% of vaccinated donors, declining with age and time since vaccination. These findings highlight the need for periodic monitoring of anti-HBs and targeted booster strategies, especially in older and occupationally exposed groups. HBsAg and NAT provide a high level of transfusion safety, while the role of routine anti-HBc testing in this low-endemic context should be carefully evaluated in view of its potential benefits and drawbacks. Donor-based surveillance is a valuable tool for evaluating long-term vaccine effectiveness and guiding public health policy. Full article

Hepatitis B virus (HBV) infection remains a global public health concern, with perinatal transmission as the primary route in endemic populations. Ayacucho is a priority region due to its high incidence (second nationally between 2019 and 2024) and the significant decline in vaccination coverage (~15%). This study aims to synthesize existing epidemiological evidence on HBV seroprevalence in Ayacucho, Peru, emphasizing temporal changes observed before and after the implementation of vaccination programs to inform control strategies. This review was conducted, integrating data from diverse population groups, including children, pregnant women, blood donors, high-risk individuals (military personnel, female sex workers, prisoners), and household contacts, to identify transmission patterns and evaluate the impact of immunization efforts. Historically, Ayacucho was hyperendemic, with an HBsAg prevalence of 20% in Huanta (1985–1986) and a high mortality from liver diseases. The introduction of a vaccination in the 1990s led to a drastic reduction in infection rates among children, from 24.4–30.4% (1994) to 2.3–5.1% (1997), and improved overall Expanded Program on Immunization (EPI) coverage. However, recent data (2000–2024) reveal a concerning increase in HBV cases since 2012, with peaks in 2016 and 2023, correlating with a decline in vaccination rates post-2021. HBV prevalence remains elevated among high-risk populations—including military personnel, female sex workers, and prisoners—as well as among blood donors (HBsAg: 3.73–5.0%; anti-HBc: 21–33%). In addition, significant knowledge gaps and low adherence to EPI strategies were observed. Despite initial vaccination success, Ayacucho faces a resurgence of HBV infection, exacerbated by declining vaccine coverage and vulnerabilities in high-risk populations. Reinforcing immunization programs and screening strategies is urgent to control and eventually eliminate HBV cases in the region. Full article

Background: Hepatitis presents a major health and economic challenge in Saudi Arabia, necessitating insight into its epidemiology, risk factors, and control measures. This review aims to synthesize current evidence on the epidemiology, risk factors, and prevention strategies for viral hepatitis in Saudi Arabia. It evaluates the effectiveness of existing interventions and proposes data-driven approaches to advance national hepatitis elimination goals. Methods: This study reviewed data from 2016 to 2024, sourced from PubMed, Google Scholar, ResearchGate, and ScienceDirect, focusing on hepatitis epidemiology and prevention in Saudi Arabia. Studies relevant to Saudi-specific trends and prevention strategies were included. Results: Saudi Arabia has achieved significant reductions in viral hepatitis prevalence, notably HBV (1.3%) due to universal infant vaccination (98% coverage), and HCV (0.124%) through the Saudi National Hepatitis Program (SNHP), which provides free DAAs (95% cure rate) and has screened 5 million people. However, challenges persist: HAV susceptibility is rising in adults (seroprevalence 33.1%), HDV affects 7.7% of HBV patients, and key risk factors include socioeconomic disparities (higher HAV/HEV in rural/low-income areas), intravenous drug use (30–50% of HCV cases), unsafe medical/cultural practices (e.g., Hijama), and limited healthcare access for migrants/rural populations. While interventions like water sanitation initiatives (58% HAV decline) and prenatal screening are effective, advancing elimination goals requires addressing gaps in HDV/HEV surveillance, outdated seroprevalence data, equitable treatment access (35% lower in rural areas), stigma reduction, and targeted strategies for high-risk groups to meet WHO 2030 targets. Conclusions: Saudi Arabia has made significant progress in hepatitis control through vaccination and public health efforts, but challenges persist. Strengthening healthcare systems, improving community engagement, and ensuring equitable access are key to sustaining elimination efforts. Full article

Blood transfusion remains vital in healthcare but poses risks, particularly from transfusion-transmissible viral infections (TTVIs). This study aims to determine the seroprevalence of HIV, HBV, and HCV among blood donors in Borgou (Benin) in 2023. This prospective, cross-sectional study involved voluntary, non-remunerated blood donors recruited via mobile campaigns and at a fixed site from January to December 2023. Screening for HIV, HBV, and HCV was performed using fourth-generation ELISA (Biorad^®). Data analysis used SPSS with Chi-square test of independence (p < 0.05), and multiple logistic regression identified independent risk factors. Among 9646 donors, 87.80% were male (sex ratio 7.19), mostly aged 18–24 (55.93%), with students forming the largest group (58.67%). Mobile units collected 70.80% of donations; 52.60% were repeat donors. Overall TTVI seroprevalence was 9.35%, with HBV (6.29%) most common, followed by HCV (1.78%) and HIV (1.28%). Chi-square tests revealed significant associations between serostatus and donor status, donation site, and occupation, but not sex. Logistic regression identified independent risk factors: age, donor status, and donation site were significantly associated with HIV infection; male sex, older age, occupation, and donor status predicted HBV infection; and only donor status was significantly associated with HCV infection. These findings highlight the need for targeted recruitment and awareness strategies to improve transfusion safety. Full article

Italy was one of the first countries to implement a hepatitis B (HBV) immunization strategy in 1991; since its introduction, the epidemiology of this disease has significantly changed. The aim of this retrospective study was to assess the seroprevalence of three HBV markers (anti-HBs, anti-HBc, and HBsAg) and describe the acquired immunity in a representative sample of the adult general population in the province of Florence (Italy) between April 2018 and December 2019. We conducted an enzyme-linked immunosorbent assay on 430 serum samples collected from the adult general population to quantify anti-HBs titers and assess the presence of anti-HBc and HBsAg. For the interpretation of hepatitis B serologic results, we referred to the US CDC guidelines. We conducted two multivariate logistic regression analyses (applied to the entire enrolled population and to the unvaccinated) to assess predictors of immunity against HBV using sex, age, and nationality as predictors. The overall anti-HBs prevalence was 30%, with a significant decreasing trend in seropositivity with increasing age. The overall anti-HBc prevalence was 11.6%, with seropositivity increasing with age. Only one subject tested positive for HBsAg (0.2%). Approximately 67.4% (290/430) of the study population was susceptible, 20.9% (90/430) was vaccinated, 9.1% (39/430) had naturally acquired immunity, and 0.2% (1/430) had an acute infection. Older age and foreign nationality were identified as risk factors in both multivariate logistic regression models. The comparison highlights a reduction in the circulation of HBV infection markers (anti-HBc and HBsAg) over 30 years in Tuscany, particularly in younger age groups. Our seroprevalence study demonstrated a good level of protection against hepatitis B, primarily among individuals under 40 years old, the target group of the vaccination strategy. Full article